Diagnostic Testing of STDs Market Size & Forecast 2033

The Diagnostic Testing Of Stds Market, estimated at USD 13.71 Bn in 2026, is expected to exhibit a CAGR of 9.8% and reach USD 26.39 Bn by 2033.

The market growth is driven by rising demand for accurate and early disease detection, supported by advances in molecular diagnostics, imaging, and point-of-care testing. Growing focus on personalized medicine, supportive healthcare policies, and ongoing R&D investments are creating new opportunities for industry players.

The strategies adopted by key market players like approvals by regulatory bodies is expected to drive the global diagnostic testing of STDs market growth over the forecast period. For instance, on January 1, 2025, Vela Diagnostics Pte. Ltd., received the U.S. Food and Drug Administration (FDA) authorization for next generation sequencing test, Sentosa SQ HIV Genotyping assay for HIV drug resistance. Traditionally, healthcare providers used to monitor the efficacy of HIV antiviral drugs viral load tests.

Global Diagnostic Testing of STDs Market – Driver

High prevalence of asymptomatic sexually transmitted infections

A significant proportion of STDs produce no visible symptoms, making laboratory screening essential for early diagnosis and treatment. According to the UK Health Security Agency’s June 2026 report, approximately 8.9 million STI tests were performed in England in 2025, of which 70.3% involved people without symptoms. The large asymptomatic population supports recurring demand for molecular assays, immunoassays, rapid diagnostic kits, instruments, reagents, and confirmatory testing services. (Source: GOV.UK)

Expansion of routine and risk-based screening recommendations

Increasing screening recommendations for adolescents, pregnant women, sexually active adults, and high-risk populations are expanding testing volumes. For instance, in March 2026, the CDC recommended annual chlamydia and gonorrhea testing for sexually active women younger than 25, while higher-risk men who have sex with men may require testing every three to six months. Pregnancy-related screening for syphilis, HIV, hepatitis B, hepatitis C, chlamydia, and gonorrhea also generates sustained diagnostic demand. (Source: CDC)

Global Diagnostic Testing of STDs Market – Opportunity

Expansion of at-home and self-testing solutions

At-home testing creates a major opportunity by improving privacy, convenience, and access for individuals reluctant to visit clinics. For instance, in January 2026, Visby Medical expanded U.S. access to its FDA-authorized at-home PCR test through Quest Diagnostics and Labcorp. The test detects chlamydia, gonorrhea, and trichomoniasis and provides results in approximately 30 minutes. Wider pharmacy, e-commerce, laboratory, and telehealth partnerships can significantly expand this segment. (Source: Visby Medical)

Strengthening of national surveillance and integrated STI programmes

Governments and public-health organizations are strengthening surveillance, asymptomatic case detection, and integration of STD testing into primary, antenatal, community, and sexual-health services. For instance, in February 2026, WHO published a consolidated STI operational handbook covering diagnostics, surveillance, partner management, and service integration. In July 2026, WHO also launched its first global STI prevalence database, containing 2,453 prevalence data points from 766 studies, supporting targeted testing programmes and funding decisions. (Source: WHO)

Global Diagnostic Testing of STDs Market – Trends

Integration of STI testing with HIV and hepatitis programmes

Healthcare systems are increasingly combining STD testing with HIV, hepatitis, antenatal, and primary-care services rather than operating separate diagnostic programmes. In July 2026, WHO called for wider adoption of multi-disease testing platforms, interoperable surveillance systems, digital-health solutions, and quality-assured STI testing. This integrated approach is encouraging demand for combination rapid tests and molecular platforms capable of processing multiple infectious-disease assays.

Rising focus on antimicrobial-resistance testing

Growing drug resistance in gonorrhea and Mycoplasma genitalium is increasing interest in culture-based susceptibility testing, molecular resistance-marker detection, and genomic surveillance. In July 2026, WHO reported that ciprofloxacin resistance in gonorrhea had reached approximately 75%, while ceftriaxone resistance was rising in some regions. A June 2026 CDC study also highlighted major gaps in global gonococcal resistance surveillance, supporting investment in resistance-informed diagnostics.

Greater Reliance on Real-Time Surveillance and Epidemiological Databases

National health programmes are increasingly using digital surveillance data to identify high-risk populations, determine testing priorities, and allocate diagnostic resources. In July 2026, WHO launched its first global STI prevalence database, initially covering chlamydia, gonorrhea, syphilis, trichomoniasis, and herpes simplex virus type 2. As of June 2026, it contained 2,453 prevalence data points from 766 studies, strengthening evidence-based screening strategies.

Shift toward integrated, people-centred diagnostic delivery

STD testing is increasingly being incorporated into primary healthcare, universal health coverage, community clinics, maternal care, and outreach programmes. In February 2026, WHO released its first consolidated operational STI handbook, providing practical guidance for integrating prevention, diagnosis, treatment, surveillance, and partner management across health systems. This trend is supporting decentralized testing and broader procurement of rapid tests, diagnostic instruments, reagents, and specimen-collection products.

Rapid Expansion of At-Home Testing and Self-Collection

STD testing is increasingly moving beyond hospitals and diagnostic laboratories through self-testing kits, mail-in specimen collection, and digitally ordered services. In March 2026, the CDC confirmed that FDA-authorized self-testing or self-collection options were available for HIV, syphilis, chlamydia, gonorrhea, and trichomoniasis. The U.K. government also invested £5 million to trial HIV home testing through the NHS App by the end of 2026.

Growing adoption of multiplex molecular testing panels

Diagnostic laboratories are adopting multiplex PCR assays that identify several sexually transmitted and reproductive-tract infections from one specimen. In July 2026, Roche received FDA clearance for its cobas BV/CV molecular assay. The same vaginal sample can also be tested using cobas assays for chlamydia, gonorrhea, trichomoniasis, and Mycoplasma genitalium, reducing repeat specimen collection and improving laboratory workflow efficiency.

Global Diagnostic Testing of STDs Market: Key Developments

On May 5, 2025, QIAGEN N.V., a Europe-based molecular diagnostic technology provider, announced that its NeuMoDx HSV 1/2 Quant Assay for the quantification and differentiation of herpes simplex virus type 1 (HSV-1) DNA and herpes simplex virus type 2 (HSV-2) received European conformity in vitro diagnostic devices (CE-IVD) certification for the European Union and other countries that accept this marking for use on NeuMoDx integrated in the Polymerase Chain Reaction (PCR) system.
In June 2026, OraSure Technologies received U.S. FDA clearance for its Colli-Pee Dx Urine Collection Kit, enabling at-home collection for sexually transmitted infection testing. The kit works with Roche’s cobas molecular systems to detect chlamydia, gonorrhea, trichomoniasis, and Mycoplasma genitalium. Its stabilization technology preserves samples at ambient temperatures, supporting private, non-invasive collection and scalable mail-in testing for laboratories, healthcare systems, and underserved populations, while expanding early diagnosis and treatment access. (Source: OraSure Technologies)
In July 2026, Seegene introduced a syndromic PCR testing approach designed to detect sexually transmitted infections and human papillomavirus simultaneously. Presented at the ADLM meeting, the method was supported by analysis of about 60,000 co-testing results. STI pathogens appeared in 82% of HPV-positive cases, while HPV was found in 46% of STI-positive cases. Seegene plans to expand evidence through its Global Million Clinical Study, supporting broader reproductive health risk assessment.
In July 2026, Roche received FDA 510(k) clearance for the cobas BV/CV molecular assay, with commercial launch expected later in 2026. Although intended for bacterial vaginosis and Candida vaginitis, the assay allows the same vaginal specimen to be used with Roche tests for chlamydia, gonorrhea, trichomoniasis, and Mycoplasma genitalium. This supports consolidated, same-sample sexual-health testing on cobas 6800/8800 systems. (Source: Roche Diagnostics)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/diagnostic-testing-of-stds-market-3917

Key Takeaways of the Global Diagnostic Testing of STDs Market

Global diagnostic testing of STDs market, is expected to exhibit a CAGR of 9.8% during the forecast period. Awareness initiatives by government and non-government organizations is expected to accelerate the market growth. For instance, on March 15, 2025, National Alliance of State and Territorial AIDS Directors, a U.S.-based public health organization partnered with Building Healthy Online Communities and TakeMeHome, project with the goal of distributing up to 1 million free HIV testing kits on a free HIV and STD test kit home delivery program. The program has already distributed more than 5,000 HIV test kits in eight states around the U.S. and is now expanding to include test kits for syphilis, gonorrhea, and chlamydia.
Among test type, the chlamydia segment is expected to dominate the global diagnostic testing of STDs market with share of 42.3% over the forecast period, owing to the launch of newer detection test kits. For instance, on March 30, 2025, the U.S. FDA allowed the use of Binx Health IO CT/NG Assay, a product of Binx Health Ltd, a U.S.-based molecular diagnostic company at point-of-care settings, such as in physician offices, community-based clinics, urgent care settings, outpatient health care facilities, and other patient care settings, operating under a Clinical Laboratory Improvement Amendments of 1988 (CLIA) Certificate of Waiver, Certificate of Compliance or Certificate of Accreditation. This action is the result of the U.S. FDA granting a waiver under the CLIA for the Binx Health IO CT/NG Assay.
Among region, North America is expected to be the dominant region in the global diagnostic testing of STDs market, owing to the increasing initiatives by the government to introduce newer cost effective rapid tests to detect STD infection. For instance, on November 15, 2025, World Health Organization recommended Simple-to-use dual HIV/syphilis Rapid Diagnostic Tests (RDTs), to eliminate mother-to-child transmission (EMTCT) of HIV and syphilis. A new partnership between Clinton Health Access Initiative (CHAI), global health organization committed to saving lives, reducing the burden of disease and strengthening health systems with MedAccess, social enterprise committed to improving health in low- and middle-income countries, and SD Biosensor, South Korea based global leader in diagnostic reagents will make these dual tests available for under US$ 1, marking it as the lowest priced WHO prequalified dual HIV/syphilis test available. This can increase rate of testing done for the syphilis and HIV which can drive the growth of the global diagnostic testing of STDs market.
The major players operating in the global diagnostic testing of STDs market include Vela Diagnostics USA Inc., Roche Holdings AG, Alere, Inc., Becton Dickinson & Company, bioMerieux, Danaher Corporation (Beckman Coulter), Hologic, Inc., binx health, Chembio Diagnostics, Pinpoint Science Inc., and bioLytical Laboratories